Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIA, Randomized, Placebo-Controlled, Single-Ascending Dose (Part A, Participant- and Investigator-Blind) and Repeated-Dose (Part B, Participant-, Investigator-, and Sponsor-Blind) Study to Investigate the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants (Part A) and in Study Participants With Moderate-to-Severe Atopic Dermatitis (Part B)

Next Previous
Trial Profile

A Phase I/IIA, Randomized, Placebo-Controlled, Single-Ascending Dose (Part A, Participant- and Investigator-Blind) and Repeated-Dose (Part B, Participant-, Investigator-, and Sponsor-Blind) Study to Investigate the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants (Part A) and in Study Participants With Moderate-to-Severe Atopic Dermatitis (Part B)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Galvokimig (Primary) ; Galvokimig (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors UCB Biopharma

Most Recent Events

  • 18 Sep 2025 Accoridng to a UCB media release, abstract on galvokimig from this trial will be presented as an oral presentation at the European Academy of Dermatology and Venereology (EADV) 2025 Congress in Paris, France, 17-20 September.
  • 18 Sep 2025 Results presented in a UCB media release
  • 18 Sep 2025 Accoridng to a UCB media release, 12-week efficacy and 18-week safety data from the phase 1/2a first-in-patient trial for galvokimig.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top